Denmark-based Novo Nordisk has dropped its fast-acting mealtime inhaled insulin product AERx due to a lack of commercial potential, and will focus on long-acting inhaled formulations instead. The problems faced by Novo in marketing the drug, including low satisfaction levels and re-imbursement issues with healthcare providers will also apply to other companies developing inhaled insulin systems.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions